Safety and Efficacy Study of Umbilical Mesenchymal Stem Cells for Liver Cirrhosis

Clinical Trial of Umbilical Mesenchymal Stem Cells Transplantation for Liver Cirrhosis-Phase I/II

Liver cirrhosis and subsequent liver failure are leading causes of morbidity and mortality worldwide. Alcohol abuse and viral hepatitis are the most common causes of cirrhosis. Novel therapies are necessary to prevent or block the process of the disease. In this current prospective cohort, the investigators plan to organize four hospitals to determine the safety and efficacy of intravenous administration of umbilical mesenchymal stem cells in the treatment of patients with liver cirrhosis in next three years.

Inclusion Criteria:

• written informed consent
• aged 30-60 years
• clinical diagnosis of compensated or decompensated liver
• child-Pugh B/C (7-12 points)
• expecting lifetime is over three years

Exclusion Criteria:

• pregnant woman
• patient with severe vascular diseases
• patient with any organ failure
• patient with any tumors
• patient with HIV
• patient who has been transplanted
• patient treated with immunosuppressors
• patient for whom the follow-up is considered impossible
• patients with any disease or condition which the investigator or treating physician feels would interfere with the trial or the safety of the subject